Articles

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Axitinib injectable suspension phase 1/2a trial enrolls first patients

Amydis announced the successful completion of a pre-investigational new drug (IND) meeting with the FDA for its candidate AMDX-2011P, a small-molecule retinal tracer that targets amyloid beta to diagnosis amyloid angiopathy.

Amydis announces successful pre-IND meeting with FDA to develop retinal tracer for amyloid angiopathy diagnosis

The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.

Saving the world: Pharmaceutical innovation in nine months

Evolving Clinical Practice: Insights Gained from Real-World Evidence

Navigating Real-World Evidence in Ophthalmology

Conducting An Audit and Using Real-World Evidence in Your Practice

Cheryl Guttman is a medical writer based in Deerfield, Ill.

Multiple challenges remain for diabetic macular edema with unmet needs to improve treatment outcomes, speed of treatment benefit, and the duration of response.



What an intravitreal integrin antagonist may bring to DME

Three risk-related baseline factors identified by this analysis may be associated with a potential need for injections.

Post hoc analysis: Protocol V provides more practical DME guidance for clinicians

Videos

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease. 

Safety and efficacy of KPI-121 0.25% for DED treatment

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.